Regeneron Surges 15% After Q3 Print as Analysts Race to Catch Up

Regeneron Pharmaceuticals rose 15.3% over the past week to $927.89, a move that left most of its closest biotech peers well behind: GILD gained 9.4%, VRTX 6.7%, and AMGN 6.1%, while KNSA was the only peer to come close, adding 20.2% on its own separate catalyst. The Q3 earnings release on October 30 was clearly the trigger, and the post-print moves in analyst targets and options positioning tell most of the story for where the stock stands now.

The most immediate consequence of Thursday's result is a wave of upward target revisions from analysts who had been sitting below the market. Citigroup raised its target to $825 from $740 while staying at Neutral, a significant move even if the rating did not shift. Canaccord, which carries a Buy, lifted to $922 from $875 on October 28, effectively matching where the stock now trades. TD Cowen had already moved to $980 before the print. The mean analyst target entering the week was $869, which now sits below the current price of $927.89, meaning the consensus has some catching up to do. The most notable pre-print upgrade came from UBS, which moved to Buy from Neutral on October 15 with a $978 target, more than 18% above where the stock was trading at the time. That call looks prescient.

The bull case is centred on Eylea HD's dosing expansion and Dupixent's breadth across eight approved conditions, with Sanofi collaboration profit sharing expected to be more favourable in the second half of the year. The bear case has narrowed since the week began: fianlimab's Phase III failure in first-line metastatic melanoma was already known, and the pipeline risk that concerned sceptics is now partially priced in, though biosimilar pressure on the older 2mg Eylea formulation remains a genuine drag. Forward earnings estimates have moved sharply higher: Regeneron ranks in the 97th percentile of the universe on forward EPS growth, and EPS momentum scores well on both 30-day and 90-day windows. At a trailing PE of 13.2 and an EV/EBITDA of 8.1, the stock does not look expensive on reported numbers, though those multiples have drifted higher over the past month in line with the price.

Options positioning has unwound almost entirely from the defensive stance described two days before the print. The put/call ratio was running at 0.90 and nearly three standard deviations above its 20-day mean at the time of that preview. It has since retreated to 0.90 again but with the 20-day mean now repriced to 0.85, the z-score has compressed to 1.6, still modestly elevated but no longer at an extreme. That compression reflects put holders who hedged ahead of results and are now exiting, rather than fresh call buying. The borrow market remains entirely uninvolved: short interest is 2.1% of the free float and has fallen 16% over the past month, borrowing costs have dropped more than 40% over the week to 0.18%, and availability is at the ceiling of what the data captures, meaning there is no friction at all in the lending market for anyone looking to establish or add to a short position.

On the company's own real-economy data, buyback spend has risen for three consecutive quarters, with the most recent quarter representing the largest Q2 for buybacks in five years at $1.17 billion. Medicaid reimbursements for Regeneron drugs have moved in the opposite direction, falling for three consecutive quarters and down 26% on the same period a year earlier, consistent with the broader narrative around formulary management and the transition away from the older Eylea formulation. Retail attention spiked sharply around the earnings release: Wikipedia page views are running more than 2.6 standard deviations above the trailing 90-day average, the highest attention reading on this metric the stock has produced in recent months.

The next scheduled earnings event is February 1, 2027. Between now and then, the question the Street will be working through is whether analyst targets reset above the stock's current level quickly enough to rebuild the implied upside that briefly disappeared this week, and whether Eylea HD volume data from Q4 channel checks can clarify how fast the mix shift away from 2mg is actually running.